A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.
← catalyst calendarNCT05683457 · readout in 198 d
Sponsored by ModernaTX, Inc. (industry) · MRNA — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Prevention
Enrollment
84actual
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-04-05 | actual | When the study began enrolling |
| Primary completion | 2027-03-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-06 | estimated | The whole study's end, after follow-up |
| First posted | 2023-01-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cytomegalovirus Infection
Interventions
- Biological: mRNA-1647
- Biological: Placebo
Primary outcomes
what the primary-completion date above is the date OFTime to the First Occurrence of an CS-CMVi Event as Measured by initiation of anti-CMV Antiviral Therapy
measured Day 100 to Month 9
Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)
measured Up to Day 187 (7 days after last study injection)
Number of Unsolicited Adverse Events (AEs)
measured Up to Day 205 (25 days after last study injection)
Number of Participants with Severe AEs
measured Up to Day 365
Number of Participants with Serious Adverse Events (SAEs)
measured Up to Day 365
Number of Participants with Grade ≥3 Acute Graft-Versus-Host Disease (GVHD)
measured Up to Day 365
Permalink · MRNA's whole pipeline · Catalyst calendar · Every registered study · What changed